

Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: a study in three European data sources

Running Head: Acute liver injury validation

Author Names:

Joan Fornas, MPH, PhD¹; Miguel Cainzos-Achirica, MD, MPH¹; Maja Hellfritzschi, MD²; Rosa Morros, MD, PhD^{3,4}; Beatriz Poblador-Plou, MPH, PhD⁵; Jesper Hallas, MD, DMSc²; Maria Giner-Soriano, PharmD, PhD^{3,4}; Alexandra Prados-Torres, MD, PhD⁵; Anton Pottegård, MSc, PhD²; Jordi Cortés, MSc^{3,6}; Jordi Castellsagué, MD, MPH¹; Emmanuelle Jacquot, MD⁷; Nicolas Deltour, MSc⁷; Susana Perez-Gutthann, MD, MPH, PhD¹; and Manel Pladevall, MD, MSc¹

Author Affiliations:

¹Epidemiology, RTI Health Solutions, Barcelona, Spain;

Address: Av. Diagonal 605, 08028, Barcelona, ES

²Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark

Address: JB Winsløvsvej 19,2, 5000 Odense C

Emails: jhallas@health.sdu.dk; apottegaard@health.sdu.dk; mmhellfritzschi@sdu.dk

Institution name (native language): Syddansk Universitet

³Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAPJGol), Barcelona, Spain; Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain

Address: Gran Via de les Corts Catalanes 587, àtic, 08007, Barcelona,

⁴Institut Català de la Salut, Barcelona, Spain

Address: Gran Via de les Corts Catalanes 587, àtic, 08007, Barcelona,

⁵EpiChron Research Group. Aragon Health Sciences Institute (IACS), IIS Aragón, REDISSEC ISCIII, Zaragoza, Spain

⁶Universitat Politècnica de Catalunya, Departament d'Estadística i Investigació Operativa, Barcelona, Spain

⁷Pharmacoepidemiology Department, Les Laboratoires Servier, Paris, France.

Correspondence:

Joan Forns, MPH, PhD

RTI Health Solutions, Av. Diagonal 605, 9-1 08028 Barcelona, Spain

Telephone: +3493.241.7761

Fax: +3493.626.896.394

E-mail: jforns@rti.org

Keywords:

Acute liver injury; validation; antidepressants

Key points:

- Case validation of acute liver injury (ALI) was conducted in two Spanish databases, EpiChron and SIDIAP, and in the Danish national registers.
- Validation of potential cases included patient profiles review and adjudication based on clinical data extracted from medical records.
- The overall PPVs obtained were higher for specific than for nonspecific codes and for hospital discharge than for outpatient codes.
- The nonspecific code “unspecified jaundice” had high PPVs for all ALI definitions in the Denmark but not in the Spanish databases.
- To maximize validity, studies on ALI should prioritize hospital specific discharge codes.

Word count: 2,898**Prior presentations:** The submitted manuscript contains original unpublished work and is not being submitted for publication elsewhere at the same time.**Sponsor(s) of research:** Les Laboratoires Servier

Abstract

Background: Validating cases of acute liver injury (ALI) in automated health data sources is challenging. Positive predictive values (PPVs) have been <60% in previous validation studies, except in one that reported PPVs >75%. Thus, we aimed to determine the ability of three ALI definitions to correctly identify ALI cases in three automated health care data sources.

Methods: Case validation was undertaken in a study conducted from 2009 to 2014 assessing the risk of ALI in users of antidepressants in databases in Spain (EpiChron and SIDIAP) and the Danish National Health Registers. Three ALI definition algorithms definitions were evaluated: primary (specific hospital discharge codes), secondary (specific and nonspecific hospital discharge codes), and tertiary (specific and nonspecific hospital and outpatient codes). The validation strategy included: review of patient profiles in EpiChron and SIDIAP and of clinical data abstracted from medical records in EpiChron and Denmark. ALI cases were considered confirmed when liver enzyme values met a definition by an international working group.

Results: Overall PPVs (95% CIs) for the algorithms used to identify potential cases of the study ALI definitions were, for the primary ALI definition, 84% (60%-97%) (EpiChron), 60% (26%-88%) (SIDIAP), and 74% (60%-85%) (Denmark); for the secondary ALI definition, 65% (45%-81%) (EpiChron), 40% (19%-64%) (SIDIAP), and 70% (64%-77%) (Denmark); and for the tertiary ALI definition, 25% (18%-34%) (EpiChron), 8% (7%-9%)

(SIDIAP), and 47% (42%-52%) (Denmark). The overall PPVs were higher for specific than for nonspecific codes and for hospital discharge than for outpatient codes. The nonspecific code “unspecified jaundice” had high PPVs for all ALI definitions in Denmark.

Conclusions: PPVs obtained apply to patients using antidepressants without preexisting liver disease or risk factors for ALI. To maximize validity, studies on ALI should prioritize hospital specific discharge codes and should include hospital codes for unspecified jaundice. Case validation is required when ALI outpatient cases are considered.

1 **Introduction**

2 Acute liver injury (ALI) is defined as a sudden appearance of liver test abnormalities and
3 includes a broad spectrum of clinical scenarios, ranging from mild abnormal biochemical
4 liver values to acute liver failure.^{1,2}

5 Previous validation studies have shown that identification of potential ALI events through
6 diagnosis and procedural codes is challenging and that most validated algorithms have
7 positive predictive values (PPVs) below 60%,³⁻⁵ except in one study, which reported PPVs
8 >75%.⁶ All previous studies highlight the need for validation by medical record review
9 when conducting studies of ALI based on automated health care data sources. This is
10 especially important in drug safety studies, in which reliance on algorithms alone for
11 automated case identification will most likely result in misclassification and overestimation
12 of the true incidence of ALI and biased effect estimates.

13 As part of a recent post-authorization safety study (PASS) conducted in five European data
14 sources investigating the potential risk of ALI associated with the use of agomelatine and
15 nine other antidepressant drugs,⁷ validation of the algorithms used to identify ALI cases
16 was conducted. This was done via medical record review in three of those data sources: two
17 Spanish health care databases and the Danish National Health Registers.

18 **Methods**

19 The objective of this study was to determine the ability of two ALI definitions to correctly
20 identify ALI cases in an automated health care data source in the context of a PASS but also
21 for future studies. Specifically, we aimed to validate the following:

- 22 ▪ An ALI definition including only main hospital discharge diagnosis codes
- 23 ▪ An ALI definition including main hospital discharge and also outpatient diagnosis
24 codes

25 In addition, within each definition, we evaluated the ways in which the specific and
26 nonspecific codes differed in validity.

27 ***Study setting***

28 Five automated health care databases were used in the agomelatine PASS.⁷ Three of these
29 in two countries were used to conduct a validation study: in Spain, the EpiChron cohort
30 from Aragon Health Sciences Institute (Aragón, Spain)⁸ and the Information System for
31 Research in Primary Care (SIDIAP) (Catalonia, Spain)⁹; and in Denmark, the Danish
32 National Health Registers (Denmark).^{10,11} The main characteristics of each database are
33 included in Supplementary eTable 1. Of the two databases that were not used, validation by
34 review of medical records is not an option in the German Pharmacoepidemiological
35 Research Database (GePaRD) (Germany)¹²⁻¹⁴ and was not feasible within the study
36 timeframe in the Swedish National Registers (Sweden).^{15,16} Nevertheless, an external
37 validation study was conducted in Germany,¹⁷ the results of which will be presented in a
38 separate publication.

39 **Identification and definition of ALI**

40 Cases of ALI were identified in cohorts of new users of the ten study antidepressants
41 evaluated in the agomelatine PASS study between 2009 and 2014⁷: citalopram,
42 agomelatine, fluoxetine, paroxetine, sertraline, escitalopram, duloxetine, venlafaxine,
43 mirtazapine, and amitriptyline. Individuals aged 18 years or older at the date of their first-
44 recorded prescription fill of any of the study antidepressants during the study period(s)
45 entered the cohort if they (1) had not received a prescription fill for the same study
46 antidepressant within the prior 12 months (new users) and (2) had at least 12 months of
47 continuous enrolment in the data source before the first prescription fill. Absence of
48 pregnancy at the start date of antidepressant use was an additional inclusion criterion for
49 women. Patients with a history of liver disease or risk factors for liver disease (e.g., alcohol
50 and drug abuse and dependence-related disorders), chronic biliary or pancreatic disease,
51 malignancy, or other life-threatening conditions (e.g., HIV infection) were excluded from
52 the study cohort (Supplementary eMethods).

53 Three algorithms corresponding to three endpoint definitions were used in the agomelatine
54 PASS to automatically identify potential ALI cases based on diagnosis codes (Table 1).^{7,18}
55 These definitions include combinations of codes that have shown higher (specific) or lower
56 (nonspecific) PPVs in previous studies.³⁻⁶ The primary ALI definition was defined as any
57 patient with a *specific* main hospital discharge diagnosis code of ALI from either the
58 *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-
59 CM) or the *International Statistical Classification of Diseases and Related Health*
60 *Problems, Tenth Revision* (ICD-10) (Table 2). The primary ALI definition was not

61 validated *per se*, but the specific codes identifying the primary ALI definition were
62 included in the secondary ALI definition, which underwent validation. The algorithm used
63 to identify potential cases of the secondary study ALI definition was defined as any patient
64 with a hospital main *specific* or *nonspecific* discharge code (ICD-9-CM or ICD-10) for
65 ALI. Finally, the algorithm for the tertiary ALI definition was assessed using specific and
66 nonspecific codes from either ICD-9-CM or ICD-10 identified in both hospital and
67 outpatient settings. In EpiChron, International Classification of Primary Care (ICPC) codes
68 were used to identify outpatient cases of the tertiary ALI definition and ICD-9-CM to
69 identify hospital cases. In SIDIAP, ICD-10-CM was used to identify primary care
70 diagnoses and ICD-9-CM to identify hospital cases. In Denmark, primary care codes were
71 not available and therefore only hospital ICD-10 codes were used both for case
72 identification and to apply exclusion criteria. The interplay between the three ALI
73 definitions is displayed in Figure 1.

74 [Add Table 1 and Figure 1 here]

75 ***Diagnostic criteria for ALI***

76 Potential cases of ALI identified with the electronic algorithms and reviewed by
77 adjudicators were considered confirmed (true positives)¹⁹ if any of the following three
78 qualifying criteria for increases in serum levels with <1 year of persistence were met
79 (aspartate transaminase [AST] levels could be used instead of ALT levels only if ALT
80 levels were unavailable and there was no known muscle pathology driving the rise in AST):

- 81 ▪ ≥ 5 x upper limit of normal (ULN) alanine aminotransferase (ALT)

- 82 ▪ ≥ 2 x ULN alkaline phosphatase (ALP)
- 83 ▪ ≥ 3 x ULN ALT and > 2 x ULN bilirubin

84 The requirement of less than 1 year of persistence of the liver function test abnormalities
85 was introduced to ensure that cases had ALI and not chronic liver injury.¹⁹ This criterion
86 was evaluated using the most recent liver enzymes results from the period 12 to 24 months
87 before the index date to check whether they were not elevated beyond 10% of the ULN (if
88 no results were available, the criterion was considered as met).

89 A *false-positive case* of ALI was defined as a potential case with enough data to be
90 evaluated but that did not meet the criteria to be classified as a confirmed case of ALI. A
91 *non-evaluable case* of ALI was defined as a potential case that lacked some of the required
92 liver enzyme results to be evaluated.

93 **Validation steps**

94 The strategy for validating potential cases identified by automated algorithms across the three
95 data sources included up to three steps: review of patient profiles (which is a deidentified
96 chronological listing of medical events and drug prescriptions and is used to detect exclusion
97 diagnoses missed by the electronic algorithm and to provide an initial assignment of case
98 status), medical record abstraction of relevant clinical data by trained health care
99 professionals, and review of abstracted data and case adjudication by trained physicians.
100 However, local adaptations were required in Denmark and SIDIAP to reflect data availability
101 and/or local regulations (Supplementary eTable 2). In Denmark, patient profiles were not
102 reviewed due to the very limited clinical information available. Also, primary care data were

103 not available. Finally, patients with study exclusion criteria not identified by hospital codes
104 were excluded during either the abstraction or the review of the abstracted information from
105 medical records. In SIDIAP, source hospital medical records were not accessible; therefore,
106 patient profile review relied only on liver enzyme results available from primary care and
107 yielded the final case classifications in this database. Cases were reviewed both by trained
108 physicians for all secondary ALI definition potential cases and by an electronic algorithm for
109 the tertiary ALI definition due to the large number of identified potential cases.

110 Several quality control checks and measures were performed. All the health care
111 professionals at each site involved in the validation, including nurses, clinical pharmacists
112 and physicians, received training on the validation processes. In EpiChron, for quality
113 control purposes, patient profiles of a random sample of ten potential cases were reviewed
114 independently by a second physician and a random sample of 25% of the confirmed cases
115 and of ten inpatient non-evaluable cases also were reviewed by a second physician. In
116 SIDIAP, for the tertiary ALI definition, an electronic algorithm evaluated all potential cases
117 and 10% of them were also evaluated manually by trained professionals blinded to the
118 study exposure. A very high level of agreement (kappa statistic equal to or larger than 0.95)
119 between the algorithm and the manual reviewers was obtained before the algorithm was
120 generalized; agreement between the two clinician reviewers was also assessed (kappa
121 statistic = 1). Similarly, in Denmark, an algorithm was created to evaluate potential cases.
122 Trained physicians manually reviewed 50 potential cases, all of which were also reviewed
123 using the automated algorithm. All potential cases were evaluated using the automated
124 algorithm only after the kappa measuring the agreement between manual review and the
125 algorithm reached 1.

126 **Statistical analyses**

127 Validity of the electronic algorithms and individual codes used to identify potential cases of
128 ALI for the secondary and tertiary ALI definitions was assessed by calculating the overall
129 PPV of the algorithm, the overall PPVs of the specific and nonspecific codes, and the PPV
130 of each individual code. PPVs for the primary ALI definition were indirectly calculated
131 through the specific codes of the secondary ALI definition. The PPV was calculated as true
132 positives/(true positives + false positives). In a sensitivity analysis, non-evaluable cases
133 were included in the PPV denominator.

134 The PPVs were computed with 95% confidence intervals (CIs) for binomial proportions by
135 the exact method using Stata software²⁰—version 12 at EpiChron and version 14 at
136 Denmark. At SIDIAP, SAS statistical software (version 9.4; SAS Institute, Inc; Cary, North
137 Carolina) and R software version 3.3.1 were used.

138 **Results**

139 The number of users of antidepressants and the final number of new users (after applying
140 inclusion/exclusion criteria) in the three databases in which validation of potential cases
141 was conducted are included Supplementary eTable 3. In EpiChron, SIDIAP, and Denmark,
142 59, 34, and 489 potential cases of the secondary ALI definition, respectively, were
143 identified; and 268, 2,826, and 1,008 potential cases of the tertiary ALI definition were
144 identified. Then, 31, 20, and 213 potential cases of the secondary ALI definition were
145 considered evaluable cases; and 134, 2,242, and 443 potential cases of the tertiary ALI

146 definition were considered evaluable cases. Of them, 20, 8, and 150 cases of the secondary
147 ALI definition and 34, 172, and 208 cases of the tertiary ALI definition were confirmed
148 (true positives) after validation (Figure 2).

149 [Add Figure 2 here]

150 Regarding the tertiary ALI definition, which includes the total number of cases for all ALI
151 definitions (see Figure 1), more than 70% of true positives in Denmark and SIDIAP and
152 56% of true positives in EpiChron were females. Overall, the age group with the highest
153 number of true positives was patients 80 years and older, followed by patients aged 50 to
154 79 years (Supplementary eTable 4).

155 The overall PPVs for the algorithm used to identify potential cases of the secondary ALI
156 definition were 65% (95% CI, 45%-81%) in EpiChron, 40% (95% CI, 19%-64%) in
157 SIDIAP, and 70% (95% CI, 64%-77%) in Denmark (Table 2). As discussed in the Methods
158 section, the primary ALI definition was indirectly validated through the specific hospital
159 discharge codes used in the secondary ALI definition, for which the overall PPVs were
160 84% (95% CI, 60%-97%) in EpiChron, 60% (95% CI, 26%-88%) in SIDIAP, and 74%
161 (95% CI, 60%-85%) in Denmark. The overall PPVs for the specific codes were higher than
162 those for the nonspecific codes in all data sources (Table 2). In EpiChron and SIDIAP, the
163 individual specific code 570.x (acute and subacute necrosis of liver) had the highest PPV,
164 while the code 573.3 (hepatitis unspecified) captured the highest proportion of true
165 positives (Table 3). In Denmark, the individual specific codes K71.2 (toxic liver disease
166 with acute hepatitis) and K71.6 (toxic liver disease with hepatitis, not elsewhere specified)

167 obtained the highest PPVs and captured the highest proportion of true positives (Table 4).
168 None of the nonspecific codes captured more than two true positives in EpiChron and
169 SIDIAP (Table 3). Conversely, in Denmark, the individual nonspecific code R17
170 (unspecified jaundice, excludes neonatal) contributed the largest number of true positives
171 and had the highest PPV among all individual specific or nonspecific hospital discharge
172 codes.

173 [Add Tables 2 and 3 here]

174 For the tertiary ALI definition, the overall PPVs were 25% (95% CI, 18%-34%) in
175 EpiChron, 8% (95% CI, 7%-9%) in SIDIAP, and 47% (95% CI, 42%-52%) in Denmark.
176 As observed for the secondary ALI definition, we observed higher PPVs for specific than
177 nonspecific codes in all data sources (Table 2). Among the individual specific codes, 570.x
178 (acute and subacute necrosis of liver) had the highest PPV in EpiChron and SIDIAP (Table
179 3 and Supplementary eTable 5). In Denmark, code K71.2 (toxic liver disease with acute
180 hepatitis) had the highest PPV among specific codes (Table 4). Among the nonspecific
181 codes, 782.4 (jaundice, unspecified, not of newborn) had the highest PPV in both EpiChron
182 and SIDIAP, although it had a low number of confirmed cases (one and two true positives
183 in EpiChron and SIDIAP, respectively). In Denmark, ICD-10 code R17 (unspecified
184 jaundice, excludes neonatal) had the highest PPV (91%) and contributed the largest number
185 of true positives. In SIDIAP, the same code used to identify primary care diagnoses had the
186 second highest PPV, and it was also the second highest contributor of true positives.
187 Regarding code R74.0 (nonspecific elevation of transaminase or LDH), it was the code
188 with the highest number of true positives, although it had a low PPV (6%).

189 [Add Table 4 here]

190 In the sensitivity analysis including non-evaluable cases in the denominator of the PPV
191 calculation, the overall PPVs for all study ALI definitions and for both specific and
192 nonspecific codes were smaller than those for the main PPV analysis in all data sources
193 (see Supplementary eTables 6 and 7).

194 **Discussion**

195 We observed consistently higher overall PPVs for specific ALI codes versus nonspecific
196 codes and higher overall PPVs for hospital discharge codes versus outpatient codes. The
197 identification of ALI cases based on hospital discharge specific codes, considered as the
198 primary ALI definition in this study, resulted in higher PPVs when compared with most
199 previously described algorithms.³⁻⁶

200 In contrast to the present study, previous studies conducted to validate ALI cases have
201 reported PPVs below 60%,³⁻⁵ or around 75%.⁶ A recently published systematic review and
202 meta-analysis including 29 studies validating drug-induced liver injury (DILI) (25 of them
203 presenting PPVs) showed a pooled PPV estimate of 14.6% (95% CI, 10.7-18.9), with PPVs
204 ranging from 1.0% to 40.2%.²¹ The authors of that study suggested that the low PPVs
205 observed in the studies might be explained by the low prevalence of DILI. In addition, a
206 different list of diagnosis codes, laboratory threshold criteria, and study drugs might be the
207 cause of the differences between studies. When we compared our study with previous
208 studies validating ALI definitions, we observed that our study differed from these previous

209 studies in different ways: Bui et al.⁶ did not exclude patients with hepatic, biliary, or
210 pancreatic diseases or cancer; Lo Re et al.³ included only cases of severe ALI; Udo et al.⁵
211 validated cases of idiopathic ALI only; and Traversa et al.⁴ validated cases of ALI
212 associated with the use of nonsteroidal anti-inflammatory drugs. In addition, there are
213 differences in the type of data sources: the Bui et al.⁶ and Lo Re et al.³ studies were
214 conducted in claims databases including inpatient and outpatient encounters, prescriptions,
215 and laboratory tests. The Traversa et al.⁴ and Udo et al.⁵ studies were conducted in hospital
216 databases in a way similar to the Danish component of our study. There are also differences
217 in the ALI definition used in previous studies compared with the criteria used in our study,
218 which were based on Aithal criteria.¹⁹ Finally, the list of codes included in the present study
219 was also different compared with those in previous studies.

220 Positive predictive values obtained in the present study for the ICD-9 specific codes 573.3
221 (hepatitis unspecified) and 570.x (acute and subacute necrosis of liver) and specific ICD-10
222 codes K71.2 (toxic liver disease with acute hepatitis) and K71.6 (toxic liver disease with
223 hepatitis, not elsewhere specified) were in line with previous studies. In Udo et al.,⁵ the
224 code 573.3 had a PPV of 80%. In Bui et al.,⁶ the PPV for individual code 570.x was 84%
225 and for 573.3 was 76%, while the PPV for the algorithm including codes 570.x, 572.2
226 (hepatic coma), or 573.3 was 74%. In Lo Re et al.,³ the PPVs for individual codes ranged
227 from 6.5% to 54.3%, the combination of codes 570.x with 572.8 (sequelae of liver disease;
228 hepatic failure) had a PPV of 100%, and code 570.x in combination with 572.2 had a PPV
229 of 67%. In addition, the authors calculated PPVs including patients with preexisting liver
230 disease, and the PPVs were higher when compared with the subset of the population that

231 excluded those patients.³ In two studies validating drug-induced ALI (DILI),^{22,23} code 573.3
232 (hepatitis unspecified) was the highest contributor of DILI cases.

233 In the present study, the nonspecific code for unspecified jaundice (R17) obtained high
234 PPVs, and it was the highest contributor of true positives in Denmark. In EpiChron and
235 SIDIAP databases, the ICD-9-CM code 782.4 (jaundice, unspecified, not of newborn) had
236 high PPVs for the secondary ALI definition (hospitalized cases), although the number of
237 true positives was one and two cases, respectively. In SIDIAP, the ICD-10 code for
238 unspecified jaundice used in the tertiary ALI definition to validate hospitalized and
239 outpatient cases was the second contributor of true positives and had the second-highest
240 PPV, although it was low (35%). Potential explanations for this discrepancy in the results
241 for unspecified jaundice code between Denmark and Spanish data sources could be the
242 following: (1) in Denmark, only hospitalized and outpatient cases from hospital outpatient
243 clinics are validated; and (2) in Denmark, exclusion criteria not identified previously were
244 applied, if identified, during either the abstraction or the review of the abstracted
245 information from medical records. These reasons may reduce the presence of false positives
246 and justify the high PPV observed for this code in Denmark compared with Spanish data
247 sources. Results observed in Denmark also contrast with those in a previous study,²³ which
248 reported that the nonspecified code for unspecified jaundice identified only a small
249 proportion of DILI cases (5% of the 265 cases in Shin et al.²³ vs. 39% of the 208 cases of
250 the tertiary ALI definition confirmed in Denmark observed in our study), but the
251 differences when validating ALI or DILI cases must be taken into account. In addition, the
252 study by Shin et al.²³ was not restricted to hospital cases as it was in Denmark, where the

253 prevalence of true ALI among outpatient primary care cases must be lower, which would
254 explain the differences observed between the two studies.

255 ***Strengths and Limitations***

256 In terms of number of validated cases, the present validation study represents one of the
257 largest efforts performed in Europe to validate ALI cases identified in automated health
258 care databases, using case-identifying algorithms, and confirmed according to consensus
259 criteria based on the presence of elevated liver enzyme levels in blood. In addition, this
260 study is the first to validate ICD-10 codes related to ALI. However, the results obtained in
261 the present study must be evaluated in the context of its limitations. An important limitation
262 of this study is that, although the ALI definitions were consistent across data sources and
263 based on blood liver enzyme levels, the approach to the evaluation of potential cases was
264 adapted to the type of information and local resources available for the validation efforts,
265 which may have impacted our findings. In SIDIAP, the validation was partial for all
266 potential cases (inpatient and outpatient), based only on liver enzyme results from primary
267 care, and no hospital medical records to validate hospital cases were available. That could
268 explain the lowest PPV for the secondary ALI definition in SIDIAP. In Denmark, only
269 outpatient potential cases from hospital outpatient clinics could be identified (primary care
270 data were not available). This is probably the reason why the difference in PPVs between
271 specific and nonspecific codes was smaller in Denmark than in the other data sources, and
272 it would also explain the higher PPVs obtained in Denmark for the secondary and tertiary
273 ALI definitions compared with the two Spanish data sources. For some codes, the number
274 of cases was low, resulting in wide CIs for the PPV. The present study has also other

275 limitations. First, we did not conduct validation of false positives, and therefore negative
276 predictive values could not be estimated. Second, the PPVs obtained in the present study
277 apply only to patients using the study antidepressant drugs who did not have preexisting
278 liver disease or risk factors for developing ALI. Third, PPVs are dependent on the ALI case
279 definition used. In the present study, we used the definition created by Aithal et al.,¹⁹ but
280 there are other case definitions that could be used^{24,25} and PPVs could have been different
281 with those other case definition criteria. Finally, PPVs are dependent on ALI prevalence.
282 Therefore, the PPVs observed in our study might not apply directly to patient populations
283 with characteristics different from those included in the present study or to studies using
284 different case definitions.

285 **Conclusions**

286 The PPVs obtained in this study apply to patients using antidepressants without preexisting
287 liver disease or risk factors for ALI. Future studies evaluating ALI in these and similar data
288 sources should prioritize use of hospital discharge and specific codes to maximize validity.
289 Moreover, case-identifying algorithms should include hospital ICD codes for unspecified
290 jaundice. In studies including nonspecific codes and outpatient cases, case validation is
291 essential.

292

293 **Acknowledgments**

294 **Funding:**

295 This study was funded by Les Laboratoires Servier under a contract granting independent
296 publication rights to the research team.

297 **Conflicts of interest:**

298 Manel Pladevall, Joan Forns, Miguel Cainzos-Achirica, Jordi Castellsagué, and Susana
299 Perez-Gutthann are employees of RTI Health, a unit of RTI International, a nonprofit
300 organization that conducts work for government, public, and private organizations,
301 including pharmaceutical companies.

302 Alexandra Prados-Torres and Beatriz Poblador-Plou are members of the EpiChron
303 Research Group on Chronic Diseases of the Aragon Health Sciences Institute (IACS),
304 ascribed to IIS Aragón, and do not have any conflict of interest with this project.

305 Maria Giner-Soriano, Rosa Morros, and Jordi Cortés worked on other projects funded by
306 pharmaceutical companies in their institution that were not related to this study and without
307 personal profit.

308 Anton Pottegård reports participation in research projects funded by Alcon, Almirall,
309 Astellas, AstraZeneca, and Servier, all with funds paid to the institution where he was
310 employed (no personal fees) and with no relation to the work reported in this paper.

311 Jesper Hallas has participated in research projects funded by Novartis, Pfizer, Menarini,
312 MSD, Nycomed, LEO Pharma, Almirall, Servier, Astellas, and Alkabello with grants paid

313 to the institution where he was employed. He has personally received fees for teaching or
314 consulting from the Danish Association of Pharmaceutical Manufacturers and from Pfizer
315 and Menarini.

316 Maja Hellfritsch has received speaker honorarium fees from Bristol-Myers Squibb and
317 Pfizer and a travel grant from LEO Pharma.

318 Nicolas Deltour and Emmanuelle Jacquot are employees of Les Laboratoires Servier.

319 **Ethics approval and informed consent:**

320 RTI International institutional review board approval to conduct the study was granted on
321 04 August 2015. The following data source-specific approvals were obtained: in EpiChron,
322 Ethics committee approval was obtained from the Comité Etico de Investigación Clínica de
323 Aragón (07 October 2015) and the Spanish Agency of Medicines and Medical Devices
324 (AEMPS) (08 September 2015). In SIDIAP, ethics committee approval was obtained from
325 the IDIAP Jordi Gol Ethics Committee (23 December 2015). In Denmark, the authorisation
326 of the Danish Data Protection Agency was granted on 15 June 2015. The Danish Health
327 Authority provided authorisation to access medical records, granted on 29 March 2016.

328 **Data availability:**

329 The data sets used for this study are owned by each of the individual research center or by
330 the government data custodians from which the research centers obtained access to the data
331 at IACS (Spain), SIDIAP (SIDIAP), BIPS (Germany), Karolinska Institutet (Sweden) and
332 Southern Denmark University (Denmark). Researchers desiring access to the data sets
333 would be required to obtain permission from research center and/or data custodians at each

334 country. Researchers desiring access to the code used to analyze that data would be
335 required to obtain permission from the research centers and the study sponsor.

336 **Authors' contributions:**

337 Authors Manel Pladevall, Jordi Castellsagué, Emmanuelle Jacquot, Nicolas Deltour and
338 Susana Perez-Gutthann planned the study. All authors made contributions to the final
339 design and final approved version of the protocol. Authors Alexandra Prados-Torres,
340 Beatriz Poblador-Plou, Maria Giner-Soriano, Rosa Morros, Jordi Cortés, Anton Pottegård,
341 Jesper Hallas, and Maja Hellfritsch undertook the statistical analysis of the different data
342 sources. Joan Forns, Miguel Cainzos-Achirica, Susana Perez-Gutthann, and Manel
343 Pladevall wrote the first draft of the manuscript. All authors contributed to and have
344 approved the final manuscript.

345 **Acknowledgments:**

346 Carla Franzoni, BSc¹, for the management of the project and coordination of activities
347 between Research Partners in SIDIAP, EpiCHron and Denmark, RTI-HS and Servier
348 teams.

349 Morten Olesen², for his contribution to the validation activities in Denmark.

350 OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense
351 Denmark, for his contribution to the validation activities in Denmark.

352

References

1. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. *Expert Opin Drug Saf* 2014;13(1):67-81. DOI: 10.1517/14740338.2013.828032
2. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. *Hepatology* 2012;55(3):965-967. DOI: 10.1002/hep.25551
3. Lo Re V, 3rd, Haynes K, Goldberg D, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. *Pharmacoepidemiol Drug Saf* 2013;22(8):861-872. DOI: 10.1002/pds.3470
4. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. *BMJ* 2003;327(7405):18-22. DOI: 10.1136/bmj.327.7405.18
5. Udo R, Maitland-van der Zee AH, Egberts TC, et al. Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. *Pharmacoepidemiol Drug Saf* 2016;25 Suppl 1:21-28. DOI: 10.1002/pds.3824

6. Bui CL, Kaye JA, Castellsague J, et al. Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users. *Curr Drug Saf* 2014;9(1):23-28.
7. Pladevall-Vila M. Post-authorisation safety study of agomelatine and the risk of hospitalisation for acute liver injury 16/01/2018 2018. <http://www.encepp.eu/encepp/viewResource.htm?id=12730> (accessed 2 March 2018).
8. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, et al. Cohort profile: the epidemiology of chronic diseases and multimorbidity. The EpiChron Cohort Study. *Int J Epidemiol* 2018. DOI: 10.1093/ije/dyx259
9. SIDIAP. Database. General details. 2014. <http://www.sidiap.org/index.php/en> (accessed 27 September 2016).
10. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015;7:449-490. DOI: 10.2147/clep.s91125
11. Pottegard A, Schmidt SA, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol* 2016. DOI: 10.1093/ije/dyw213

12. Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. *Pharmacoepidemiol Drug Saf* 2008;17(3):215-223. DOI: 10.1002/pds.1545
13. Jobski K, Kollhorst B, Garbe E, Schink T. The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone-Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case-Control Study. *Drug Saf* 2017;40(6):505-515. DOI: 10.1007/s40264-017-0511-8
14. Jobski K, Schmedt N, Kollhorst B, Krappweis J, Schink T, Garbe E. Characteristics and drug use patterns of older antidepressant initiators in Germany. *Eur J Clin Pharmacol* 2017;73(1):105-113. DOI: 10.1007/s00228-016-2145-7
15. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. *BMC Public Health* 2011;11:450. DOI: 10.1186/1471-2458-11-450
16. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months. *Pharmacoepidemiol Drug Saf* 2007;16(7):726-735. DOI: 10.1002/pds.1294
17. Timmer A, Kappen S, de Sordi D, et al. Validity of hospital ICD-10-GM codes to identify acute liver injury. Presented at the 34th International Conference on

Pharmacoepidemiology and Therapeutic Risk Management; August 22-26 2018.
Prague, Czech Republic.p. 262.

18. Pladevall-Vila M, Pottegard A, Schink T, et al. Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources. *CNS Drugs* 2019. DOI: 10.1007/s40263-019-00611-9
19. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. *Clin Pharmacol Ther* 2011;89(6):806-815. DOI: 10.1038/clpt.2011.58
20. StataCorp LP. *Stata User's Guide: Release 14*. StataCorp LP: College Station, Tex., 2015.
21. Tan EH, Low EXS, Dan YY, Tai BC. Systematic review and meta-analysis of algorithms used to identify drug-induced liver injury (DILI) in health record databases. *Liver Int* 2018;38(4):742-753. DOI: 10.1111/liv.13646
22. Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. *Am J Gastroenterol* 2007;102(11):2437-2443. DOI: 10.1111/j.1572-0241.2007.01456.x
23. Shin J, Hunt CM, Suzuki A, Papay JI, Beach KJ, Cheetham TC. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical

record data. *Pharmacoepidemiol Drug Saf* 2013;22(2):190-198. DOI:
10.1002/pds.3388

24. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. *J Hepatol* 1990;11(2):272-276.
25. FDA. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. US Food and Drug Administration, 2009.
<https://www.fda.gov/downloads/guidances/UCM174090.pdf> (accessed 1 June 2018).

Tables

Table 1. ICD-9-CM and ICD-10 Codes Relevant to Acute Liver Injury

Code	Description
Specific codes	
ICD-9-CM	
570.x	Acute and subacute necrosis of liver
572.2	Hepatic coma
573.3	Hepatitis unspecified
ICD-10	
K71.0	Toxic liver disease with cholestasis
K71.1	Toxic liver disease with hepatic necrosis
K71.2	Toxic liver disease with acute hepatitis
K71.6	Toxic liver disease with hepatitis, not elsewhere classified
K71.9	Toxic liver disease, unspecified
K72.0	Acute and subacute hepatic failure
K72.9	Hepatic failure, unspecified
K75.9	Inflammatory liver disease, unspecified
K76.2	Central hemorrhagic necrosis of liver
Nonspecific codes	
ICD-9-CM	
573.8	Other specified disorders of liver
573.9	Unspecified disorders of liver
782.4	Jaundice, unspecified, not of newborn
V42.7	Liver transplant
790.4	Nonspecific elevation of transaminase or lactic acid dehydrogenase
789.1	Hepatomegaly
ICD-10	
K76.8	Other specified diseases of liver
K76.9	Liver disease, unspecified
R17	Unspecified jaundice, excludes neonatal
R16.0	Hepatomegaly, not elsewhere classified
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified

Code	Description
R74.0	Nonspecific elevation of transaminase and lactic acid dehydrogenase
Z94.4	Liver transplant
ICPC	
D97	Liver disease (specified or unspecified)
D13	Jaundice
D23	Hepatomegaly
A91	Abnormal results investigations

ICD-9-CM = *International Classification of Diseases, Ninth Revision, Clinical Modification*;

ICD-10 = *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision*;

ICPC = *International Classification of Primary Care*.

Table 2. Positive Predictive Values (PPVs) of Study ALI Definitions and of Overall Specific and Nonspecific Codes Used to Identify Potential Acute Liver Injury (ALI) Cases (Non-evaluable Cases Not Included)

	EpiChron			SIDIAP			Denmark		
	Total ^a	TP	PPV, % (95% CI) ^b	Total ^a	TP	PPV, % (95% CI) ^b	Total ^a	TP	PPV, % (95% CI) ^b
Secondary ALI definition ^c	31	20	64.5 (45.4-80.8)	20	8	40.0 (19.1-63.9)	213	150	70.4 (63.8-76.5)
Specific codes ^d	19	16	84.2 (60.4-96.6)	10	6	60.0 (26.2-87.8)	50	37	74.0 (59.7-85.4)
Nonspecific codes	12	4	33.3 (9.9-65.1)	10	2	20.0 (2.5-55.6)	163	113	69.3 (61.6-76.3)
Tertiary ALI definition	134	34	25.4 (18.3-33.6)	2,242	172	7.7 (6.6-8.9)	443	208	47.0 (42.2-51.7)
Specific codes	18	15	83.3 (58.6-96.4)	46	16	34.8 (21.4-50.2)	73	50	68.5 (56.6-78.9)
Nonspecific codes	116	19	16.4 (10.2-24.4)	2,196	156	7.1 (6.1-8.3)	370	158	42.7 (37.6-47.9)

CI = confidence interval; SIDIAP = Information System for Research in Primary Care; TP = true positives.

^a Total of evaluable cases. Non-evaluable cases for the secondary and tertiary ALI definitions were 9 and 104 in EpiChron, 14 and 584 in SIDIAP, and 28 and 66 in Denmark.

^b PPV was calculated as $PPV = \text{confirmed cases} / (\text{true positives} + \text{false positives})$. Results are presented as positive predictive values (%) and their 95% CIs.

^c The number of cases of the secondary ALI definition with specific codes did not necessarily match the number of cases for the primary ALI definition because, for example, a case qualifying as a primary ALI definition with a specific code could also qualify as a secondary ALI definition with a nonspecific code. If the latter scenario happened first, for the secondary ALI definition, this case would be computed in the nonspecific codes group rather than in the specific codes group.

^d Equivalent to the PPVs for the study primary ALI definition (specific hospital discharge codes).

Table 3. Positive Predictive Values (PPVs) of Specific and Nonspecific Codes Used to Identify Potential Acute Liver Injury (ALI) Cases: Secondary (Regular Font) and Tertiary (Italics) ALI Definitions in Data Sources Using ICD-9-CM Codes (Non-evaluable Cases Not Included)^a

	EpiChron			SIDIAP		
	Total	TP	PPV, % (95% CI) ^b	Total	TP	PPV, % (95% CI) ^b
Specific codes						
570.x Acute and subacute necrosis of liver						
Secondary ALI definition	5	5	100.0 (47.82-100.0)	3	3	100.0 (29.2-100.0)
<i>Tertiary ALI definition</i>	5	5	100.0 (47.8-100.0)	1	1	100.0 (2.5-100.0)
572.2 Hepatic coma						
Secondary ALI definition	1	0	0.0 (0.0-97.5)	0	-	-
<i>Tertiary ALI definition</i>	1	0	0 (0-97.5)	0	-	-
573.3 Hepatitis unspecified						
Secondary ALI definition	13	11	84.6 (54.6-98.1)	7	3	42.9 (9.9-81.6)
<i>Tertiary ALI definition</i>	12	10	83.3 (51.6-97.9)	4	3	75.0 (19.4-99.4)
Nonspecific codes						
573.8 Other specified disorders of liver						
Secondary ALI definition	9	2	22.2 (2.8-60.0)	6	0	0.0 (0.0-45.9)
<i>Tertiary ALI definition</i>	9	2	22.2 (2.8-60.0)	5	0	0.0 (0.0-52.2)
573.9 Unspecified disorders of liver						
Secondary ALI definition	1	0	0.0 (0.0-97.5)	0	0	-
<i>Tertiary ALI definition</i>	0	0	-	0	0	-
782.4 Jaundice, unspecified, not of newborn						

	EpiChron			SIDIAP		
	Total	TP	PPV, % (95% CI) ^b	Total	TP	PPV, % (95% CI) ^b
Secondary ALI definition	1	1	100 (2.5-100)	2	2	100 (15.8-100)
<i>Tertiary ALI definition</i>	1	1	100 (2.5-100)	2	2	100 (15.8-100)
V42.7 Liver transplant						
Secondary ALI definition	0	-	-	0	-	-
<i>Tertiary ALI definition</i>	0	-	-	0	-	-
790.4 Nonspecific elevation of transaminase or LDH						
Secondary ALI definition	1	1	100.0 (2.5-100.0)	2	0	0.0 (0.0-84.2)
<i>Tertiary ALI definition</i>	1	1	100.0 (2.5-100.0)	1	0	0.0 (0.0-97.5)
789.1 Hepatomegaly						
Secondary ALI definition	0	-	-	0	0	-
<i>Tertiary ALI definition</i>	0	-	-	0	0	-

CI = confidence interval; ICD-9-CM = *International Classification of Diseases, Ninth Revision, Clinical Modification*; LDH = lactic acid dehydrogenase; TP = true positives.

Note: PPVs for the ICPC codes used to define cases for the tertiary ALI definition in EpiChron are presented in eTable 5.

^a The number of cases of the secondary ALI definition with specific codes did not necessarily match the number of cases for the primary ALI definition because, for example, a case qualifying as a primary ALI definition with a specific code could also qualify as a secondary ALI definition with a nonspecific code. If the latter scenario happened first, for the secondary ALI definition, this case would be computed in the nonspecific codes group rather than in the specific codes group.

^b PPV was calculated as $PPV = \text{confirmed cases} / (\text{true positives} + \text{false positives})$. Results are presented as positive predictive values (%) and their 95% CIs.

Table 4. Positive Predictive Values (PPVs) of Specific and Nonspecific Codes Used to Identify Potential Acute Liver Injury (ALI) Cases: Secondary (Regular Font) and Tertiary (Italics) ALI Definitions in Data Sources Using ICD-10-CM Codes (Non-evaluable Cases Not Included)

	SIDIAP ^a			Denmark ^b		
	Total	TP	PPV, % (95% CI) ^c	Total	TP	PPV, % (95% CI) ^c
Specific codes						
K71.0 Toxic liver disease with cholestasis						
Secondary ALI definition				n < 5	n < 5	50.0 (1.3-98.7)
<i>Tertiary ALI definition</i>	0	-	-	5	n < 5	60.0 (14.7-94.7)
K71.1 Toxic liver disease with hepatic necrosis						
Secondary ALI definition				5	n < 5	40.0 (5.3-85.3)
<i>Tertiary ALI definition</i>	0	-	-	6	n < 5	33.3 (4.3-77.7)
K71.2 Toxic liver disease with acute hepatitis						
Secondary ALI definition				9	8	88.9 (51.8-99.7)
<i>Tertiary ALI definition</i>	0	-	-	13	12	92.3 (64.0-99.8)
K71.6 Toxic liver disease with hepatitis, not elsewhere classified						
Secondary ALI definition				8	7	87.5 (47.3-99.7)
Tertiary ALI definition	5	2	40.0 (5.3-85.3)	9	8	88.9 (51.8-99.7)
K71.9 Toxic liver disease, unspecified						
Secondary ALI definition				5	n < 5	80.0 (28.4-99.5)

	SIDIAP ^a			Denmark ^b		
	Total	TP	PPV, % (95% CI) ^c	Total	TP	PPV, % (95% CI) ^c
<i>Tertiary ALI definition</i>	1	0	0.0 (0.0-97.5)	12	6	50.0 (21.1-78.9)
K72.0 Acute and subacute hepatic failure						
Secondary ALI definition				7	6	85.7 (42.1-99.6)
<i>Tertiary ALI definition</i>	3	2	66.7 (9.4-99.2)	9	8	88.9 (51.8-99.7)
K72.9 Hepatic failure, unspecified						
Secondary ALI definition				10	6	60.0 (26.2-87.8)
<i>Tertiary ALI definition</i>	8	1	12.5 (0.3-52.7)	13	7	53.8 (25.1-80.8)
K75.9 Inflammatory liver disease, unspecified						
Secondary ALI definition				n < 5	n < 5	66.7 (9.4-99.2)
<i>Tertiary ALI definition</i>	23	7	30.4 (13.2-52.9)	5	n < 5	60.0 (14.7-94.7)
K76.2 Central hemorrhagic necrosis of liver						
Secondary ALI definition				n < 5	n < 5	100 (2.5-100)
<i>Tertiary ALI definition</i>	0	-	-	n < 5	n < 5	100 (2.5-100)
Nonspecific codes						
K76.8 Other specified diseases of liver						
Secondary ALI definition				16	n < 5	6.3 (0.2-30.2)
<i>Tertiary ALI definition</i>	111	1	0.9 (0.0-4.9)	35	n < 5	11.4 (3.2-26.7)
K76.9 Liver disease, unspecified						

	SIDIAP ^a			Denmark ^b		
	Total	TP	PPV, % (95% CI) ^c	Total	TP	PPV, % (95% CI) ^c
Secondary ALI definition				30	15	50.0 (31.3-68.7)
<i>Tertiary ALI definition</i>	116	11	9.5 (4.8-16.3)	107	33	30.8 (22.3-40.5)
R17 Unspecified jaundice, excludes neonatal						
Secondary ALI definition				79	75	94.9 (87.5-98.6)
<i>Tertiary ALI definition</i>	57	20	35.1 (22.9-48.9)	90	82	91.1 (83.2-96.1)
R16.0 Hepatomegaly, not elsewhere classified						
Secondary ALI definition				7	n < 5	42.9 (9.9-81.6)
<i>Tertiary ALI definition</i>	52	3	5.8 (1.2-15.9)	12	n < 5	25.0 (5.5-57.2)
R16.2 Hepatomegaly with splenomegaly, not elsewhere classified						
Secondary ALI definition				n < 5	n < 5	75.0 (19.4-99.4)
<i>Tertiary ALI definition</i>	0	-	-	6	n < 5	50.0 (11.8-88.2)
R74.0 Nonspecific elevation of transaminase and LDH						
Secondary ALI definition				27	16	59.3 (38.8-77.6)
<i>Tertiary ALI definition</i>	1,85	119	6.4 (5.4-7.6)	120	33	27.5 (19.7-36.4)
Z94.4 Liver transplant						
Secondary ALI definition				0	-	-
<i>Tertiary ALI definition</i>	0	-	-	0	-	-

CI = confidence interval; ICD-10-CM = *International Classification of Diseases, Tenth Revision, Clinical Modification*; LDH = lactic acid dehydrogenase; TP = true positives.


^a In SIDIAP, ICD-10 codes were used only for the outpatient codes of the study tertiary ALI definition.

^b Due to data protection policies in Denmark, the exact number of cases could not be provided when the number of cases was less than five.

^c PPV was calculated as $PPV = \text{confirmed cases} / (\text{true positives} + \text{false positives})$. Results are presented as positive predictive values (%) and their 95% CIs.


Figures

Figure 1. Definition of the Study ALI Definition Algorithms^a



^a ALI definition refers to the case-identifying algorithms only. By definition, the secondary ALI definition in the analysis included only cases confirmed after validation.

Figure 2. Flowchart With the Flow of Potential Cases Through the Case Validation Process: Secondary (Regular Font) and Tertiary (Italics) ALI Definitions



Note: In each cell, the first number refers to secondary ALI definitions and the second number refers to tertiary ALI definitions.

Note: One hundred fifteen patients did not undergo further validation due to the lack of additional hospital data for those cases. Among them, 3 were classified as true positives, 69 as false positives, and 35 were considered non-evaluable during patient profile review.

^b One hundred seven patients identified on ambulatory codes and with lack of additional hospital data were directly adjudicated during the patient profile phase.

^c Patients with study exclusion criteria not identified by hospital codes were excluded during the abstraction or review of medical records.